Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/12/26 16:04 | 5/8/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Herr Amy E. | MN | D | 3 | M.d | 753 | 49.39 | 0 | 15 | 3 | I | ||||||||||||||||
5/12/26 16:04 | 5/8/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Herr Amy E. | MN | D | 3 | S.d | -753 | 49.39 | 0 | -15 | 3 | I | ||||||||||||||||
5/7/26 17:26 | 5/5/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Hippel James | MN | O | CFO | 2 | M.d | 2,951 | 23.80 | 0 | 124 | 418 | 154 | D | ||||||||||||||
5/7/26 17:24 | 5/5/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Bohnen Shane | MN | O | SVP - GC | 2 | M.d | 400 | 37.51 | 0 | 11 | 7 | D | |||||||||||||||
5/7/26 17:22 | 5/5/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Kelderman Kim | MN | DO | CEO | 3 | M.d | 1,271 | 17.05 | 0 | 75 | 66 | D | |||||||||||||||
5/5/26 16:12 | 5/1/26 | TECH | Health | BioPrd | Biological Products, (No Diag | Crouse Steven C. | MN | O | P - Diag | 1 | M.d | 0 | 0.00 | 0 | 1 | 14 | 6 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |